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ABSTRACT
Expression of epithelial-specific integrin ανβ6 is up-regulated in various aggressive
cancers and serves as a prognostic marker. Integrin-targeted PET imaging probes
have been successfully developed and tested in the clinic. Radiotracers based on the
peptide A20FMDV2 derived from foot-and-mouth disease virus represent specific and
selective PET ligands for imaging ανβ6-positive cancers. The present study aims to
describe the radiolabeling, in vitro and in vivo evaluation of a bi-terminally PEGylated
A20FMDV2 conjugated with DOTA or PCTA for 64Cu radiolabeling. Stability studies
showed radiolabeled complexes remained stable up to 24 h in PBS and human serum.
In vitro cell assays in CaSki cervical cancer cells and BxPC-3 pancreatic cancer cells
confirmed that the peptides displayed high affinity for αvβ6 with Kd values of ~50 nM.
Biodistribution studies revealed that [64Cu] Cu-PCTA-(PEG28)2-A20FMDV2 exhibited
higher tumor uptake (1.63 ± 0.53 %ID/g in CaSki and 3.86 ± 0.58 %ID/g in BxPC-3
at 1 h) when compared to [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 (0.95 ± 0.29 %ID/g
in CaSki and 2.12 ± 0.83 %ID/g in BxPC-3 at 1 h) . However, higher tumor uptake
was accompanied by increased radioactive uptake in normal organs. Therefore,
both peptides are appropriate for imaging ανβ6-positive lesions although further
optimization is needed to improve tumor-to-normal-tissue ratios.

INTRODUCTION

have been shown in various cancers including pancreatic,
cervical, non–small cell lung cancer and oral squamous
cell carcinoma [10–13].
Several ανβ6-targeting ligands have been
identified and used in preclinical therapeutic and
imaging studies. Hausner et al. used a 20-mer peptide
(NAVPNLRGDLQVLAQKVART; A20FMDV2) that
showed preferential binding to ανβ6 [14]. Another 20mer peptide (RGDLATLRQLAQEDGVVGVR; H2009)
isolated from a phage-display peptide library by panning
on a lung adenocarcinoma cell line also binds to the
restrictively expressed integrin ανβ6 [13]. Kimura et al.
demonstrated that highly stable cystine knot peptides
have potent and specific integrin ανβ6 binding for cancer
detection [15]. The shared sequence of “RGDLXXL” (X
represents unspecified amino acid) in the central binding
region is key to high binding affinity and good selectivity

Integrins are a class of receptors that play essential
roles in mediating cell adhesion, making transmembrane
connections to the cytoskeleton, and modulating many
intracellular signaling pathways [1, 2]. Because of their
diverse functions, integrins have been studied extensively
for decades, leading to the design and development of
integrin antagonists in the treatment of multiple types of
cancers. In recent years, ανβ6 has received much attention
where its overexpression has been discovered to promote
malignant behavior and tumor progression, resulting in
poor prognosis and a striking reduction in survival rates for
cancer patients [3–7]. ανβ6 has many regulatory functions
in oncogenesis and its interaction with fibronectin and/or
activation of TGFβ1 are known to lead to invasion and
cancer migration [8, 9]. Increased expression levels of ανβ6
www.oncotarget.com
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Table 1: Summary of in vitro and in vivo studies for investigated ανβ6-targeting ligands
64

Cu-DOTA conjugate

Cu-PCTA conjugate

64

Labeling Conditions

45°C for 1 h

80°C for 15 mins

Molar Activity (GBq/µmol)

18.5

18.5

Labeling Efficiency

>95%

>98%

Human Serum Stability

98.9% at 24 h

100% at 24 h

Kd (nM)

62.4 ± 3.7 (CaSki)
37.6 ± 5.4 (BxPC-3)

60.4 ± 6.7 (CaSki)
38.1 ± 4.7 (BxPC-3)

Bmax (# receptors per cell)

0.75 ± 0.03 × 105 (CaSki)
1.15 ± 0.10 × 105 (BxPC-3)

0.73 ± 0.02 × 105 (CaSki)
1.27 ± 0.02 × 105 (BxPC-3)

Tumor Uptake at 1 h p.i (%ID/g)

0.95 ± 0.29 (CaSki)
2.12 ± 0.83 (BxPC-3)

1.63 ± 0.53 (CaSki)
3.86 ± 0.58 (BxPC-3)

towards ανβ6 integrin [16, 17]. Phage display libraries
confirmed that RGD sequence followed by an LXXL
motif is crucial in targeting ανβ6, while having minimal
interactions with ανβ3, ανβ5, and αIIbβ3 [16].
This study focuses on the 20-amino-acid,
A20FMDV2, derived from the foot-and-mouth disease
virus, which was used as a first-generation radiotracer
for targeting ανβ6 in vivo [14]. A20FMDV2 was initially
labeled with 18F and showed specific binding to ανβ6
both in in vitro cell assays and in vivo tumor-bearing
models [18–20]. Though the initial lead compound
A20FMDV2 exhibited good affinity towards integrin
ανβ6, in vivo studies in tumor mouse models showed
rapid excretion, metabolic breakdown, and unexpected
high and persistent levels of radioactivity in nontarget organs. To improve the pharmacokinetics of
peptides, modifications such as cysteine amino acid
substitutions, cyclization, PEGylation and incorporation
of non-proteinogenic amino acid substitutes have
been introduced [21–23]. Bi-terminal PEGylation of
the peptide resulted in favorable in vitro and in vivo
behavior concerning ανβ6 cell binding affinity and
tumor uptake in mouse models [23]. This led to the
first-in-human microdose study to assess the safety and
pharmacokinetics of [18F]FBA-(PEG28)2-A20FMDV2
which confirmed the favorable performance of biterminally PEGylated peptide for identification of
small lesions in primary sites as well as common sites
of metastatic diseases [24].
However, radiolabeling of A20FMDV2 with
64
Cu (T1/2 12.7 h, β+ = 17%, β− = 39%, EC = 43%, Emax
= 0.656 MeV) would allow for easier radiochemical
synthesis compared to 18F and allow for later imaging
time points where contrast might be improved.
Previous studies have used mono-PEGylated
A20FMDV2 conjugated with various chelators and
evaluated after radiolabeling with 64Cu [25, 26]. The
goal of the present study is to use the optimized biterminally PEGylated A20FMDV2 conjugated with
either DOTA (S-2-(4-isothiocyanatobenzyl)-1,4,7,10www.oncotarget.com

tetraazacyclododecane-tetraacetic acid) or PCTA
(3,6,9,15-tetraazabicyclo[9.3.1] pentadeca-1(15),11,13triene-4-S-(4-isothiocyanatobenzyl)-3,6,9-triacetic acid)
and evaluate these constructs in vitro and in vivo after
radiolabeling with 64Cu. We chose to evaluate these two
chelators because it is known that DOTA does not form
the most kinetically stable complexes with copper and
therefore we hypothesized that the PCTA peptide would
have a better in vivo profile than the DOTA peptide.

RESULTS
Macrocyclic chelator integrin ανβ6 targetting
peptides
Bi-terminally PEGylated A20FMDV2 were custom
synthesized and conjugated with DOTA and PCTA
(Figure 1) and found to be >93 % pure by HPLC and
confirmed by mass spectrometry.

Radiochemistry
The radiolabeling results of the peptides with 64Cu
is shown in Table 1. Radiolabeled products were obtained
in high radiochemical purity (>95%) as determined by
radio-HPLC and used without further purification. The
molar activity of both radiolabeled peptides was 18.5
GBq/µmol. HPLC retention times were 8:05 and 8:37
min for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 and
[64Cu]Cu-PCTA-(PEG28)2-A20FMDV2, respectively
(Supplementary Figure 1). Similarly, radio-TLCs
demonstrated more than 95% radiochemical purity
(Supplementary Figure 2).

Serum stability
In vitro stability studies of all radiotracers were
assessed by incubating in PBS 1X and human serum.
There was less than 4% loss of 64Cu in PBS or human
serum observed at 24 h (Supplementary Figure 3).
361
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Flow cytometry

Radioligand saturation binding

Flow cytometry (Supplementary Figure 4)
confirmed the expression level of integrin ανβ6 on CaSki
and BxPC-3 cells with MFUs of 12.4 ± 0.1 and 11.1 ± 0.3
respectively when incubated the ανβ6-positive antibody as
compared to the control antibody (0.4 ± 0.1 for CaSki cells
and 1.2 ± 0.1 for BxPC-3 cells). Expression values on the
SiHa and ME-180 cell lines were 0.4 ± 0.1 and 1.5 ± 0.1,
respectively, demonstrating the relatively high expression
level on CaSki and BxPC-3 cells.

Receptor-binding affinity of the radiolabeled
peptides to ανβ6 was evaluated on CaSki and BxPC-3 cell
lines using a saturation binding assay at 4°C. Binding
affinities were investigated by determining the equilibrium
dissociation constant (Kd) and the maximum binding
capacity (Bmax) of radiolabeled conjugates to integrin ανβ6
-positive cells. Representative saturation binding curves
in CaSki and BxPC-3 cell lines are shown in Figure 3. Kd
values for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 (62.4
± 3.7 nM) and [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2
(60.4 ± 6.7 nM) were similar for CaSki cells and slightly
better when evaluated on BxPC-3 cells (37.6 ± 5.4 nM
for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 and 38.1 ±
4.7 nM for [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2). The
Bmax was calculated to be about 0.75 × 105 receptors per
cell in CaSki cell line, whereas BxPC-3 has a maximum
binding capacity of approximately 1.20 × 105 receptors per
cell for both radiotracers.

Cell binding and internalization
Both radiolabeled peptides showed binding to ανβ6–
expressing cell lines that were significantly inhibited by
blocking with A20FMDV2, demonstrating ανβ6-specific
binding (Figure 2). The binding was similar between the
two peptides [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 and
[64Cu]Cu-DOTA-(PEG28)2-A20FMDV2. The binding
of both peptides in CaSki and BxPC-3 cells increased
rapidly over a 2-h time frame and then plateaued for
subsequent time points. More than 75% of the total bound
radioactivity was internalized into the cells. Radiolabeled
[64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 peptide was
internalized into the cells at a steady rate from 4% at
15 mins to 18% at 2 h in CaSki cells and from 5% at 15
mins to 20% at 2 h in BxPC-3 cells. Similar behavior was
observed for [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 in
which internalization increased from 4% at 15 mins to
18% at 2 h in CaSki cells, and from 6% at 15 mins to 23%
at 2 h in BxPC-3 cells.

Biodistribution studies
Biodistribution of the radiolabeled peptides was
studied at 1, 4, and 24 h post-injection. Figure 4 shows
the biodistribution of both peptides in mice bearing
CaSki xenografts. Both showed rapid blood clearance
with only 0.26 ± 0.07 %ID/g for [64Cu]Cu-DOTA(PEG28)2-A20FMDV2 and 0.53 ± 0.10 %ID/g for
[64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 remaining in
the blood at 24 h. Overall accumulation of radioactivity
in tumors and non-target organs was higher for [64Cu]

Figure 1: Structures of the ανβ6-targeting ligands investigated herein.
www.oncotarget.com
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Cu-PCTA-(PEG28)2-A20FMDV2
than
[64Cu]CuDOTA-(PEG28)2-A20FMDV2. High kidney uptake was
observed for [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2
at 113.58 ± 38.31 %ID/g at 1 h p.i, which decreased to
24.38 ± 6.54 %ID/g at 24 h. On the other hand, high and
persistent retention of radioactive uptake in kidney was
observed for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2, as
evidenced by an accumulation of 42.72 ± 4.03 %ID/g at
1 h p.i followed by a slight decrease to 37.04 ± 10.60
%ID/g at 4 h and remained at 20.99 ± 4.67 %ID/g at
24 h. Despite [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2
having higher kidney uptake at the initial time points,
both the peptides eventually decreased to similar levels
at 24 h.
Biodistribution profiles in BxPC-3 tumor-bearing
mice were similar to those of CaSki (Figure 5). Tumor
uptake of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 (3.86
± 0.58 %ID/g) was higher than that of [64Cu]Cu-DOTA(PEG28)2-A20FMDV2 (2.12 ± 0.83 %ID/g) at 1 h p.i and
exhibited good tumor retention with a slight decrease at the
4 h time point (3.09 ± 0.77 %ID/g) and an uptake of 2.45 ±
0.57 %ID/g at 24 h. Despite showing higher accumulation
in normal organs compared to [64Cu]Cu-DOTA-(PEG28)2A20FMDV2, [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2
shows shorter retention of activity in normal organs, as
indicated by kidney uptake decreasing from 105.39 ±
13.58 %ID/g at 1 h to 28.65 ± 8.45 %ID/g at 24 h.

Between the two radiolabeled peptides, tumor-tonormal-tissue ratios were generally similar for the two
peptides (Supplementary Tables 1 and 2). Despite the fact
that [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 has a twofold higher tumor uptake in vivo, it was compensated
by increased radioactive uptake in non-target organs.
Blocking studies with unlabeled A20FMDV2 confirmed
the specific uptake of the peptides in integrin ανβ6positive tumors. Injection of excess unlabeled peptide
resulted in a statistically significant reduction in binding
of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 in CaSki
tumors at 1 h p.i (0.67 ± 0.26 %ID/g with blocking
compared to 1.63 ± 0.53 %ID/g without blocking, p =
0.02). There was a reduction in binding of [64Cu]CuDOTA-(PEG28)2-A20FMDV2, but this did not reach
significance (0.65 ± 0.17 %ID/g with blocking compared
to 0.95 ± 0.29 %ID/g without blocking, p = 0.12). In
the BxPC-3 tumor mouse model, blocking resulted in
significantly reduced uptake of both radiotracers with
0.71 ± 0.16 %ID/g in tumors compared to 2.12 ± 0.83
%ID/g for [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 (p =
0.005) and 0.75 ± 0.09 %ID/g compared to 3.86 ± 0.58
%ID/g for [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 (p
< 0.001). Normal organs where significant (p < 0.05)
blocking occurred include the lung, kidney, muscle,
and heart and indicate expression of ανβ6 in these tissues
(Supplementary Tables 3 and 4).

Figure 2: Representative binding and internalization curves of radiotracers in vitro in (A) CaSki cell line (B) BxPC-3 cell line. Total bound
and internalization levels were shown as percent relative to total radioactivity. Data are presented as triplicates of mean ± SD.
www.oncotarget.com
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PET/CT imaging

DISCUSSION

Small animal PET/CT images of [64Cu]Cu-DOTA(PEG28)2-A20FMDV2 and [64Cu]Cu-PCTA-(PEG28)2A20FMDV2 at 1, 4, and 24 h are shown in Figures 6
and 7. These figures show a representative single slice
of the coronal PET/CT images for mice bearing BxPC-3
xenografts. These images show good tumor uptake of both
radiolabeled constructs at all three time points that was
inhibited by an excess of blocking agent. Images show
clearance of the radioactivity from the normal tissues
and tumor over time. Image analysis of the tumors shows
that SUVmaxs increase from 0.44 ± 0.02 at 1 h to 0.57 ±
0.15 at 4 h to 0.69 ± 0.09 at 24 h for [64Cu]Cu-DOTA(PEG28)2-A20FMDV2 due to the more rapid clearance of
radioactivity from normal tissue compared to tumors. A
similar trend was observed for [64Cu]Cu-PCTA-(PEG28)2A20FMDV2 which showed SUVmaxs increasing from 0.46
± 0.04 at 1 h to 0.54 ± 0.05 at 4 h to 0.74 ± 0.21 at 24 h.
In addition, tumor specificity is confirmed as the mice that
received blocking agent had significantly smaller SUVs (p
< 0.044) compared to the non-blocked mice.

Integrin ανβ6, expressed exclusively in epithelial
cells, lends itself to be an excellent molecular target for
imaging and therapy as it is not expressed in normal adult
epithelia but is expressed under special wound healing
conditions and in cancer [3–7]. In fact, overexpression of
integrin ανβ6 has been observed in various forms of cancer
including those of pancreatic, cervical, non–small cell
lung cancer and oral squamous cell carcinoma [10–13].
Previous research has shown the correlation between ανβ6
expression with more aggressive disease, reduced survival
rates and increased chance of metastasis. Therefore, the
design and development of ανβ6-targeting peptides that can
serve as both imaging and therapeutic agents would be
valuable. In this regard, the 20-mer peptide, A20FMDV2,
has been extensively studied due to its specific binding
toward integrin ανβ6 [14]. The lead peptide was optimized
and radiolabeled with 18F for imaging with a bi-terminal
PEG construct used for first-in-human studies [24].
The purpose of this study was to evaluate A20FMDV2
for radiolabeling with copper for potential imaging or

Figure 3: Representative saturation binding curves of radiotracers in (A) CaSki cell line (B) BxPC-3 cell line. Y-axis represents fmol of
[64Cu]Cu-labeled bi-terminally PEGylated peptides bound to integrin ανβ6 -positive cells. Data are presented as triplicates of mean ± SD.
www.oncotarget.com
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Figure 4: Biodistribution of 64Cu radiotracers in mice bearing ανβ6-expressing CaSki xenograft tumors (A) Radiotracer uptake of [64Cu]
Cu-DOTA-(PEG28)2-A20FMDV2 (B) Radiotracer uptake of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 in tumors and selected organs
(%ID/g; bars = SD; tumors: n = 4 per time point) (ns: no significant, *p < 0.05, T-test).

Figure 5: Biodistribution of 64Cu radiotracers in mice bearing ανβ6-expressing BxPC-3 xenograft tumors (A) Radiotracer uptake of [64Cu]
Cu-DOTA-(PEG28)2-A20FMDV2 (B) Radiotracer uptake of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 in tumors and selected organs
(%ID/g; bars = SD; tumors: n = 4 per time point) (**p < 0.01, ***p < 0.001, T-test).
www.oncotarget.com
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therapy. Previous studies investigated 64Cu labeling,
only with mono-PEGylation, which is not optimal [25,
26]. Therefore, this study employed the bi-terminally
PEGylated peptide conjugated to DOTA or PCTA for
radiolabeling with 64Cu. The two peptides are compared
in vitro and in vivo.
All radiotracers were radiolabeled in good
radiochemical purity (>95 %) at a molar activity of 18.5
GBq/μmol (0.50 Ci/μmol). The molar activity of the
DOTA conjugated peptide is comparable to previously
published results by Hu et al. (0.48 Ci/μmol) and Hausner
et al. (0.58–0.60 Ci/μmol) despite the additional PEG28
[25, 26]. This indicates that the introduction of another
PEG28 does not affect the complexation of 64Cu with
DOTA. Labeling of the PCTA peptide at 45°C resulted
in 72% labeling; therefore we increased the temperature

to 80°C for 15 mins to achieve >95% labeling. It is not
clear why higher temperatures are needed as other studies
have showed efficient 64Cu-labeling of PCTA conjugates
at room temperature [27, 28], while some have used
temperatures >60°C [29, 30]. While the in vitro serum
stability cannot predict in vivo degradation from the
liver and other organs, it can be used as a first screen and
showed that both peptides were stable enough to warrant
further in vivo investigation.
Similar to Hu et al., more than 75% of bound
radioactivity of the two chelates were internalized by 1
h in both CaSki and BxPC-3 cells [25]. While the total
amount of bound radioactivity at 1 h was less than 60%
observed by Hu et al. for the [64Cu]Cu-DOTA labeled
A20FMDV2 peptide, this could be due to the use of
different cell lines or the additional PEG28 in our studies

Figure 6: Representative micro-PET/CT co-registration images of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 in athymic
nude mice bearing BxPC-3 tumors (n = 3). PET imaging was performed at (A) 1 h, (B) 4 h, (C) 24 h after intravenous injection of
3.7 MBq of [64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 with or without blocking. White arrows indicate the positions of the tumor xenografts.
The scale bar unit is Bq/mL (D) Maximum standared uptake values of imaged tumors (*p < 0.05, T-test).
www.oncotarget.com
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[25]. The saturation binding showed good affinity of
30–60 nM for both peptides when evaluated in CaSki or
BxPC-3 cells. This is generally lower than the reported
1.73 ± 0.46 nM for [111In]In-DTPA-A20FMDV2, which
can be due to the introduction of PEGylation onto the
original peptide [31]. The Bmax values for BxPC-3 were
twice as higher for CaSki cells, which is supported by the
higher tumor uptake of radiotracers in BxPC-3 compared
to CaSki tumor models.
It was observed that [64Cu]Cu-PCTA-(PEG28)2A20FMDV2 had higher tumor uptake than [64Cu]CuDOTA-(PEG28)2-A20FMDV2 in both CaSki and BxPC-3
tumor-bearing mice. The tumor uptake of [64Cu]Cu-PCTA(PEG28)2-A20FMDV2 (3.86 ± 0.58 %ID/g) in BxPC-3
tumor mouse model is slightly lower than the uptake
of 4.7 ± 0.9 %ID/g achieved by [18F]FBA-(PEG28)2-

A20FMDV2 [23] and is higher that of [64Cu]Cu-DOTA(PEG28)2-A20FMDV2 (2.12 ± 0.83 %ID/g), which agrees
with the Bmax data. Tumor uptake was specific for all of
the constructs except for [64Cu]Cu-DOTA-(PEG28)2A20FMDV2 in the CaSki tumors which is likely due to
the lower expression of ανβ6 in this model. PET imaging
in mice bearing BxPC-3 tumors confirmed the specific
tumor targeting of both radiotracers towards integrin
ανβ6 which indicates their potential as imaging agents for
integrin ανβ6. However, the higher tumor uptake of [64Cu]
Cu-PCTA-(PEG28)2-A20FMDV2 compared to [64Cu]CuDOTA-(PEG28)2-A20FMDV2 that was observed in the
biodistribution studies was not seen in the PET imaging
studies as the SUVs were similar at all time points. This
may be due to the greater amount of mass of peptide (1–2
μg for imaging vs. 0.1–0.2 μg for biodistribution) that was

Figure 7: Representative micro-PET/CT co-registration images of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 in athymic
nude mice bearing BxPC-3 tumors (n = 3). PET imaging was performed at (A) 1 h, (B) 4 h, (C) 24 h after intravenous injection of
3.7 MBq of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 with or without blocking. White arrows indicate the positions of the tumor xenografts.
The scale bar unit is Bq/mL (D) Maximum standard uptake values of imaged tumors (*p < 0.05, **p < 0.01, ***p < 0.001, T-test).
www.oncotarget.com
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injected for the imaging studies which may have partially
blocked tumor uptake.
Overall, uptake in normal organs of [64Cu]Cu-PCTA(PEG28)2-A20FMDV2 was generally higher than that of
[64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 at the earlier time
points (1 and 4 h), especially in the kidney. The increased
kidney uptake of [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2
may be due to its +2 charge compared to the +1 charge of
[64Cu]Cu-DOTA-(PEG28)2-A20FMDV2. Cationic portions
of peptides may form electrostatic interactions with negative
surface charge of proximal tubular cells of kidney, resulting
in the trapping of the radiotracers and their metabolites in
the tubular cells [32, 33]. Higher uptake in other tissues for
[64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 and in particular
the liver may be due to the higher lipophilicity of PCTA
compared to DOTA. In addition, there may be expression
of ανβ6 in normal organs such as the lung, kidney, muscle,
and heart due to inhibition of radiolabeled peptide uptake
by an excess of unlabeled peptide (Supplementary Tables 3
and 4). Previous pre-clinical studies have not investigated
expression in normal organs, however, clinical evaluation
of similar peptides has shown low uptake in the brain, bone,
liver, and lung indicating the potential value of imaging
metastases in these sites.
In
conclusion,
[64Cu]Cu-PCTA-(PEG28)264
A20FMDV2 and [ Cu]Cu-DOTA-(PEG28)2-A20FMDV2
bound specifically to ανβ6 on tumor cells both in vitro
and in vivo. While in vivo tumor uptake [64Cu]Cu-PCTA(PEG28)2-A20FMDV2 was superior to that of [64Cu]CuDOTA-(PEG28)2-A20FMDV2, the normal tissue uptake of
[64Cu]Cu-PCTA-(PEG28)2-A20FMDV2 was also greater.
Thus, both peptides have similar tumor to normal tissue
ratios and would be equally good for imaging and therapy,
which contradicts our hypothesis that [64Cu]Cu-PCTA(PEG28)2-A20FMDV2 would be superior. Future work will
focus on modifications of the peptides to improve affinity
and tumor to normal tissue ratios by possibly cyclizing the
peptide and substituting more hydrophilic amino acids in
positions that do not adversely affect binding.

Washington, DC, USA). Reversed-phase high-pressure
liquid chromatography (HPLC) was used to evaluate the
radiolabeling efficiency. HPLC utilized a two-solvent
system: water (0.05% trifluoroacetic acid (TFA)) and
acetonitrile (0.05% TFA). The system was equipped with
UV absorbance detectors (UV, 220 and 280 nm), a NaI
radiotracer detector and a photodiode array detector. HPLC
analysis of peptides used Kinetex (Phenomenex) C-18
column (5 μm, 4.6 × 150 mm I.D.).

Cell culture
CaSki and BxPC-3 cell lines purchased from ATCC
(Manassas, VA, USA) were revived from liquid nitrogen
storage and cultured at 37°C, 5% CO2. The media for
CaSki cells contained DMEM, 10% heat-inactivated
fetal bovine serum (FBS) (Gibco), and 10 mM HEPES.
The media for BxPC-3 cells contained RPMI 1640, 10%
FBS, and 10 mM HEPES. Cell-labeling solutions and
biodistribution samples were analyzed on a Beckman
Gamma 8000 counter containing a NaI crystal (Beckman
Instruments, Inc., Irvine, CA, USA).

Radiochemical synthesis of [64Cu]Cu-DOTA(PEG28)2-A20FMDV2 and [64Cu]Cu-PCTA(PEG28)2-A20FMDV2
Cu was produced from 64Ni(p,n)64Cu nuclear
reaction on enriched 64Ni on a TR-19 biomedical
cyclotron (Advanced Cyclotron Systems, Inc. - Canada)
at Mallinckrodt Institute of Radiology, Washington
University School of Medicine, and purified with an
automated system using standard procedures [34, 35]. The
resulting activity was diluted in 0.1M HCl at a specific
activity ranging from 300 to 2000 mCi/μg. An aliquot
of 2 µl DOTA-(PEG28)2-A20FMDV2 peptide (2 nmol)
was diluted to 100 µl with 0.1M NH4OAc (pH 5.5). A
stock solution of 64Cu in 0.1M HCl was diluted ten-fold
with 0.1M NH4OAc (pH 5.5) for radiolabeling and 1mCi
of 64Cu was added to the reaction mixture. The reaction
mixture was incubated at 45°C for 1 h. The product
was evaluated for radiochemical purity by radio-HPLC
and TLC with a mobile phase of 50 mM DTPA. The
radiolabeled complex remained at the origin in the TLC
system, while the free 64Cu moved with solvent front.
The synthesis of [64Cu]Cu-PCTA-(PEG28)2A20FMDV2 was similar to [64Cu]Cu-DOTA-(PEG28)2A20FMDV2 except that reaction solution was incubated
at 80°C for 15 mins. Quality control was performed by
TLC and HPLC as described above.
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MATERIALS AND METHODS
General information
All solvents and reagents were purchased from
Sigma-Aldrich (St. Louis, MO, USA) or Fisher Scientific
(Pittsburgh, PA, USA) and used as received unless stated
otherwise. All solutions and buffers were prepared using
HPLC-grade water. Peptides were custom synthesized and
characterized by AnaSpec (Fremont, CA, USA). Stock
solutions of the peptides (1 nmol/µl) were prepared in
HPLC-grade water and stored at −20°C before use. NonPEGylated A20FMDV2 peptide served as blocking agent.
Radio-TLCs employed Whatman 60 Å silica gel thinlayer chromatography (TLC) plates and were analyzed
using a Bioscan 200 imaging scanner (Bioscan, Inc.,
www.oncotarget.com

Serum stability
100 μl of human serum albumin (HSA 1g/ml) or
1X Phosphate Buffered Saline (PBS) was prepared in
Eppendorf tubes, followed by the addition of 100 μl of
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Cu-radiolabeled peptides. The resulting reaction mixtures
were incubated at 37°C with moderate agitation. At time
points of 1, 4 and 24 h, aliquots (0.5 µl) were withdrawn
from the sample and spotted on TLC plates. RadioTLCs with a mobile phase of 50 mM diethylenetriamine
pentaacetate (DTPA) was performed to evaluate the
fraction of intact radiotracer at specific time points.

PEGylated peptide was prepared to 10 µg/100 µl in PBS
1X as a blocking agent. Assay tubes were pretreated with
5% bovine serum albumin (5% wt/v in PBS) to block
non-specific binding. A solution of 100 µL cells (2 ×
106 cells) and 100 µl of blocking or PBS were added to
each assay tube, followed by a series of 64Cu-radiolabeled
peptide concentrations that ranged between 5 nM and
1000 nM. Tubes were slightly agitated and placed on ice
for 1 h. After incubation, tubes were centrifuged for 3
mins, and the supernatant was removed. Cell pellets were
washed with ice-cold PBS three times and measured for
activity on a gamma counter to determine the amount of
surface-bound radioactivity. The experiments were done
in triplicate in the presence and absence of a 1000-fold
excess blocking agent. Saturation binding curves were
generated with x-axis as the molarity of radiolabeled
peptides vs. y-axis as specific binding in fmol. Curves
were fitted with GraphPad Prism 9 to find the equilibrium
constant (Kd) and the maximum binding capacity (Bmax).

64

Flow cytometry
Wash buffer of PBS 1X, 0.1% BSA, and 0.1%
sodium azide was prepared. Confluent cells were harvested
and re-suspended in wash buffer. Aliquots of 3 × 105 cells
in 96-well-plate were incubated with 100 µl primary Ab
10D5 (ανβ6 positive) (10 µg/mL in FACS buffer) at room
temperature for 1 h, 500 rpm. After washing the cells three
times with wash buffer, cells were incubated in 100 µl of
Alexa Fluor 488 goat-anti-mouse (10 µg/mL diluted to
1:50 in FACS buffer) for 30 mins at room temperature.
Cells were then rinsed and re-suspended in a final volume
of 200 µl wash buffer. In control samples, the primary Ab
10D5 antibody was replaced by IgG2a Isotype Control
(ανβ6 negative). Flow cytometric analysis was performed
using a FACScan flow cytometer and data presented as
mean fluorescence units (MFUs).

Biodistribution studies
Animals were supplied by Charles River
Laboratories (Wilmington, MA, USA), and were
handled in compliance with the Guidelines for Care
and Use of Research Animals established by the
Division of Comparative Medicine and the Animal
Studies Committee of Washington University School
of Medicine under protocol #20–0214. Female athymic
nude mice were inoculated on the right flank with 10 ×
106 CaSki or 5 × 106 BxPC-3 cells. Tumors were allowed
to grow until they approached approximately 100 mm3
in volume. Radiolabeled peptides were diluted in saline
to a dose of 0.37 MBq (10 µCi) per 100 µl. Animals
were injected intravenously with 0.37 MBq (10 µCi) of
[64Cu]Cu-DOTA-(PEG28)2-A20FMDV2 or [64Cu]CuPCTA-(PEG28)2-A20FMDV2 peptides and sacrificed
by cervical dislocation at 1, 4, and 24 h. For blocking
experiments, non-PEGylated peptide (100 µg in 100
µL saline) was injected ten minutes before radiotracer.
Blood, lung, liver, spleen, kidney, muscle, heart, bone,
and tumor were harvested. The amount of radioactivity
in each organ was determined by gamma counting, and
the percent injected dose per gram of tissue (% ID/g) was
calculated.

Cell binding and internalization
For 64Cu cell-binding experiments, a method similar
to that described by Geissler et al. was used [36]. Briefly,
3.7 KBq (0.1μCi) aliquots of [64Cu]Cu-DOTA-(PEG28)2A20FMDV2 or [64Cu]Cu-PCTA-(PEG28)2-A20FMDV2
was added to a cell suspension of either CaSki or BxPC-3
cells in PBS 1X (pH 7.4; 2.0 × 106 cells in 50 µl). Assay
tubes were pretreated with 5% bovine serum albumin
(5% wt/v in PBS) to block non-specific binding. Reaction
mixtures were incubated at various time points (15 mins,
30 mins, 1 h, 2 h, 4 h and 6 h) with moderate shaking to
prevent cell settling. Cells were centrifuged and supernatant
was aspirated from cell pellets. The pellets underwent
additional washes with 0.5 mL ice-cold PBS (3 times) and
the fraction of bound radioactivity was measured with a
gamma counter. To determine the fraction of internalized
radiotracers, cells were treated with 2 × 0.5 mL of 20 mM
sodium acetate (pH 4.0) for 5 mins to remove surfacebound radioactivity. Following centrifugation, cells
were washed with 0.5 mL ice-cold PBS and counted for
activity. To determine the specific binding towards ανβ6,
non-PEGylated peptide (20 μg) was added 10 mins before
the addition of radiotracers as a blocking agent. The
experiments were performed in triplicate.

PET/CT imaging
BxPC-3 cells (5 × 106) were inoculated in the
right shoulder of female athymic nude mice 3–4 weeks
before PET imaging sessions. All the experiments
involving animals followed the Guidelines for Care and
Use of Research Animals established by the Division of
Comparative Medicine and the Animal Studies Committee
of Washington University School of Medicine under
protocol #20–0214. On the day of the experiment, mice

Radioligand saturation binding
A cell suspension of 1.0 × 108, either CaSki or
BxPC-3 cells in 5 mL PBS was prepared. The nonwww.oncotarget.com
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